Avita Medical | 1811094D

Stock Price
1.31
Daily Change
-0.03 -1.87%
Monthly
-6.09%
Yearly
-50.19%
Q3 Forecast
1.33


Financials
Assets AUD 79.71M
Cash and Equivalent AUD 14.05M
Cost of Sales AUD 2.28M
Current Assets AUD 57M
Current Liabilities AUD 20.16M
Debt AUD 45.99M
EBIT AUD -10.27M
EBITDA AUD -9.86M
Employees AUD 87
EPS Earnings Per Share AUD -0.21
Equity Capital and Reserves AUD 4.5M
Gross Profit on Sales AUD 16.13M
Interest Expense on Debt AUD 1.35M
Loan Capital AUD 42.25M
Market Capitalization AUD 175.79M
Net Income AUD -11.59M
Operating Expenses AUD 28.36M
Operating Profit AUD -9.96M
Pre-Tax Profit AUD -11.57M
Sales Revenues AUD 18.41M
Selling and Administration Expenses AUD 21.23M
Stock AUD 7.27M
Trade Creditors AUD 6.29M
Trade Debtors AUD 11.96M
Peers Price Chg Day Year Date
Celltrion 169,600.00 -400.00 -0.24% -13.38% Sep/09
Cspc Pharmaceutical 11.26 -0.22 -1.92% 146.93% Sep/09
Sino Biopharmaceutical 8.91 -0.10 -1.11% 186.50% Sep/09
Zhangzhou Pientzehuang Pharmaceutical 204.40 -1.40 -0.68% 0.90% Sep/09
Kangmei Pharma 2.02 -0.02 -0.98% 14.77% Sep/09
Adcock Ingram Holdings 7,225.00 38.00 0.53% 11.24% Sep/08
Cochlear 299.28 -0.61 -0.20% 4.50% Sep/09
CSL 209.83 -3.54 -1.66% -30.41% Sep/09
Clinuvel Pharmaceuticals 10.83 -0.11 -1.01% -26.53% Sep/09
Divis Laboratories Ltd 6,017.00 -10.50 -0.17% 16.30% Sep/09
Knight Therapeutics 6.45 0.01 0.16% 14.56% Sep/08
Dianthus Therapeutics 31.80 5.30 20.00% 14.18% Sep/08
Malin Corporation 7.90 -0.10 -1.25% 25.40% Sep/08
Medical Developments International 0.57 -0.002 -0.35% 33.65% Sep/09
Mayne Pharma 4.59 0.09 1.89% -4.08% Sep/09
Nanosonics 3.89 -0.11 -2.75% 6.58% Sep/09
Neuren Pharmaceuticals 20.19 -0.62 -2.96% 46.16% Sep/09
Organigram Holdings 2.27 -0.01 -0.44% -8.47% Sep/08
Paradigm Biopharmaceuticals 0.26 -0.02 -5.45% 4.00% Sep/09
Pacific Edge 0.14 -0.001 -0.70% 34.29% Sep/09
Pharma Mar 87.95 -0.45 -0.51% 112.13% Sep/08
Polynovo 1.40 -0.07 -4.63% -43.24% Sep/09
PYC Therapeutics 1.25 -0.01 -0.79% -3.85% Sep/09
Qiagen NV 40.52 0.13 0.32% -1.06% Sep/08
Ramsay Health Care 33.70 -0.19 -0.56% -13.70% Sep/09
ResMed 42.37 0.45 1.06% 14.47% Sep/09
Laboratorios Farma 59.90 0.25 0.42% -27.17% Sep/08
Sartorius 195.25 2.05 1.06% -22.61% Sep/08
Telix Pharmaceuticals 13.96 0.36 2.65% -23.09% Sep/09
Tilray 1.53 -0.11 -6.71% -34.05% Sep/08

Indexes Price Day Year Date
Australia All Ordinaries 9072 -55.10 -0.60% 10.40% Sep/09

Avita Medical Inc traded at 1.31 this Tuesday September 9th, decreasing 0.03 or 1.87 percent since the previous trading session. Looking back, over the last four weeks, Avita Medical lost 6.09 percent. Over the last 12 months, its price fell by 50.19 percent. Looking ahead, we forecast Avita Medical Inc to be priced at 1.33 by the end of this quarter and at 1.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.